Natascha Roehlen
Freiburg, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Claudin-1 targeting suppresses tumor growth, invasion, and metastasis in patient-derived cholangiocarcinoma models.
Journal: Science translational medicine
Published: June 03, 2026
Predicting Decompensation in Unresectable Hepatocellular Carcinoma on Atezolizumab Plus Bevacizumab: The ARTE Score.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: February 13, 2026
Single-cell profiling reveals diverse γδ T cell subsets in ulcerative colitis.
Journal: Science immunology
Published: February 06, 2026
Hepatocellular Carcinoma - from Immunobiology to Immunotherapy.
Journal: Zeitschrift fur Gastroenterologie
Published: January 26, 2026
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 28, 2025
Interdisciplinary strategies for the prevention and treatment of MASLD
Journal: Deutsche medizinische Wochenschrift (1946)
Published: October 10, 2025
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma.
Journal: Journal of hepatology
Published: September 04, 2025
Albumin-muscle density score predicts overall survival in patients with hepatocellular cancer undergoing treatment with transarterial chemoembolization.
Journal: Journal of cancer research and clinical oncology
Published: October 17, 2024
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study.
Journal: The Lancet. Digital health
Published: October 01, 2024
Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple Myeloma.
Journal: Vaccines
Published: September 24, 2024
Claudin-1 is a mediator and therapeutic target in primary sclerosing cholangitis.
Journal: Journal of hepatology
Published: September 13, 2024
Last Updated: 09/26/2026